Unique ID issued by UMIN | UMIN000049841 |
---|---|
Receipt number | R000056775 |
Scientific Title | Clinical Effects of Delgocitinib Ointment on Skin Barrier Dysfunction in Pediatric Atopic Dermatitis |
Date of disclosure of the study information | 2022/12/22 |
Last modified on | 2024/01/03 18:55:06 |
Clinical Effects of Delgocitinib Ointment on Skin Barrier Dysfunction in Pediatric Atopic Dermatitis
Clinical Effects of Delgocitinib Ointment on Skin Barrier Dysfunction in Pediatric Atopic Dermatitis
Clinical Effects of Delgocitinib Ointment on Skin Barrier Dysfunction in Pediatric Atopic Dermatitis
Clinical Effects of Delgocitinib Ointment on Skin Barrier Dysfunction in Pediatric Atopic Dermatitis
Japan |
Atopic Dermatitis
Pediatrics |
Others
NO
To evaluate the clinical efficacy of topical delgocitinib on skin barrier dysfunction in atopic dermatitis.
Efficacy
Change in TEWL and SCH from baseline to 12 weeks
Change in TARC, SCCA2, EASI, pEASI and vIGA from baseline to 12 weeks
TEWL, SCH, and questionnaire scores for eczematous and non-eczematous areas at 12 weeks
TARC, SCCA2, EASI, pEASI and vIGA at 12 weeks
EIS results at baseline and at 12 weeks, and findings from tape stripping
Interventional
Parallel
Non-randomized
Open -no one is blinded
No treatment
3
Treatment
Medicine |
Corectim group
Colectim ointment twice a day, but Lidomex ointment can be used in case of eczema exacerbation.
Steroid group
Lidomex ointment twice daily, if eczema improves, patients may be switched to Proactive therapy. Protopic ointment may be used on the head and neck area.
Non-AD group
No treatment
6 | months-old | <= |
12 | years-old | >= |
Male and Female
Pediatric patients with atopic dermatitis who have eczema on the elbow fossa with vIGA-AD score of 2 or higher
(1) Patients with a history of use of group II or higher topical steroids or delgocitinib ointment on the forearm within 1 month
(2) Patients with signs of infection on the forearm
(3) Patients with a history of use of biological drugs within 1 year or who are going to use biological drugs during participation in the study
(4) Other patients deemed inappropriate as research subjects by the principal investigator
70
1st name | Sakura |
Middle name | |
Last name | Sato |
National Hospital Organization Sagamihara National Hospital
Clinical Research Center for Allergy and Rheumatology
252-0392
18-1 Sakuradai, Minamiku, Sagamihara, Kanagawa
042-742-8311
ssakura8010@foodallergy.jp
1st name | Akira |
Middle name | |
Last name | Kawai |
National Hospital Organization Sagamihara National Hospital
Department of pediatrics
252-0392
18-1 Sakuradai, Minamiku, Sagamihara, Kanagawa
042-742-8311
akawai-ykh@umin.ac.jp
National Hospital Organization Sagamihara National Hospital
Torii Pharmaceutical Co.,Ltd
Profit organization
Sagamihara Hospital Ethics Committee of the National Hospital Organization
18-1 Sakuradai, Minamiku, Sagamihara, Kanagawa
042-742-8311
makino.megumi.bn@mail.hosp.go.jp
NO
2022 | Year | 12 | Month | 22 | Day |
Unpublished
Open public recruiting
2022 | Year | 10 | Month | 01 | Day |
2022 | Year | 12 | Month | 13 | Day |
2022 | Year | 12 | Month | 22 | Day |
2024 | Year | 06 | Month | 30 | Day |
2022 | Year | 12 | Month | 20 | Day |
2024 | Year | 01 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056775
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |